Entremed, Inc. Entremed Research Emphasizing Low-Dose Cancer Therapy
Featured at Annual Meeting of American Association for Cancer Research
April 4, 2000. EntreMed, Inc. (NASDAQ:ENMD) announced today that
low-doses of EndostatinЩ have the potential to significantly reduce cancer progression. A
total of eleven scientific abstracts presented by EntreMed scientists and collaborators are
featured at the 91st Annual Meeting of the American Association for Cancer Research
(AACR) in San Francisco from April 1-5, 2000.
EntreMed's research is highlighted with a late-breaking abstract entitled, Efficacy of
Recombinant Human EndostatinЩ Protein at Low Doses.ФThis report provides preclinical
evidence that peritumoral administration of EndostatinЩ, at concentrations 2,000-fold less
than that required to inhibit tumor progression in previously published reports using
systemic dosing, significantly deters the development of a variety of tumors in mice.
EndostatinЩ is currently in Phase I clinical trials through Dana-Farber Partners CancerCare,
the M. D. Anderson Cancer Center and the University of Wisconsin. Preliminary data
presented at the National Cancer Institute's semi-annual Phase I progress meeting held in
February showed encouraging results regarding EndostatinЩ's safety, and indicated
potential effects of EndostatinЩ on biological measures in cancer patients with progressive
disease. Full results will not be available until data from patients have been thoroughly
analyzed upon completion of studies in the next few months.
Dr. John W. Holaday, EntreMed Chairman, President and Chief Executive Officer
commented on the significance of low-dose chemotherapy research findings such as those
presented by EntreMed and others: In keeping with reports at this years AACR meeting, the
April 1st issue of Cancer Research features an article,УAntiangiogenic Scheduling of
Chemotherapy Improves Efficacy Against Experimental Drug-resistant CancerФby Dr.
Timothy Browder, Dr. Judah Folkman and their team of scientists at the Laboratory of
Surgical Research at Children's Hospital, Boston, which was sponsored in part by EntreMed
funding. We are encouraged by these latest confirmatory research findings indicating that
the addition of angiogenesis inhibitors to new schedules of low-dose chemotherapy may
ultimately provide enormous clinical benefit to cancer patients.
EntreMed has filed patent applications covering the use of standard or low-dose
angiogenesis inhibitors with conventional standard or low-dose chemotherapy.
Dr. Edward R. Gubish, EntreMed's Executive Vice President for Research and
Development, further commented: As presented at AACR on Monday, our preclinical
programs with both EndostatinЩ and Angiostatinо were designed to support testing of
different routes of administration and a range of doses of these agents in cancer patients. As
our Phase I studies with EndostatinЩ progress, we have initiated plans for testing low doses
of EndostatinЩ in cancer patients using continuous infusion and subcutaneous administration
in a further Phase I study to be conducted in Europe.
The AACR is a professional society with more than 14,000 laboratory and clinical
scientists engaged in cancer research in the United States, Canada and 60 other countries.
Its principal activities include fostering advances in cancer and biomedical research through
programs that promote scientific education and communication and allow scientists to
present significant new discoveries in cancer research and development
Rockville, MD-based EntreMed, Inc. The Angiogenesis CompanyЩ is a leader in the field
of antiangiogenesis research, which studies the inhibition of abnormal blood vessel growth
recently associated with a broad range of diseases such as cancer and atherosclerosis. The
Company's strategy is to accelerate development of its core technologies through
collaborations and sponsored research programs with university medical departments,
research companies and government laboratories. For further information, please visit the
EntreMed web site at www.entremed.com.
Statements herein that are not descriptions of historical facts are forward-looking and subject to risk and uncertainties. Actual
results could differ materially from those currently anticipated due to a number of factors, including those set forth in the Company's
Securities and Exchange Commission filings under "Risk Factors," including risks relating to the early stage of products under
development; uncertainties relating to clinical trials; dependence on third parties; future capital needs; and risks relating to the
commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability,
supply, competition and other risks).
To
contact us or report problems with pages E-mail
